Masimo Corporation (MASI) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Definitive $180 cash takeover by Danaher announced 2026-02-17 created a large premium and sharp momentum; stock trades below the deal price with near-term catalysts (2/26 earnings call, evolving shareholder litigation) driving an attractive event-arbitrage spread over the next few days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Operating Margins ⢠Healthy Liquidity ⢠Below-Line Drag MASI's core business remains strong with solid margins and free cash flow, but heavy below-the-line losses, leverage, and a negative net result make the investment case mixed and valuation look stretched.
Price Behavior
Key Price Behavior Insights: ⢠Tight range ⢠Support holding ⢠Resistance capped Support Level: $178.3-$178.4 Resistance Level: $178.7-$178.8 MASI has been drifting slightly higher in a tight range over the last month, with buyers defending support but limited upside follow-through near resistance.
Sentiment & News
Key News Insights: ⢠Deal Fairness ⢠ITC Setback ⢠Mixed Holdings Masimo is facing merger-fairness scrutiny over the proposed Danaher deal while the ITC's rejection of its Apple Watch import-ban bid and mixed institutional moves keep sentiment pressured.
AI Summary
MASI is now best viewed as an event-driven merger-arb trade rather than a pure operating story, with the $180 Danaher deal anchoring valuation and making transaction executionânot earnings upsideâthe main driver; the key takeaway is that the core business still generates cash, but near-term upside is capped unless the deal breaks, while legal/process risk remains the main downside.
Description
Masimo designs and manufactures noninvasive physiological monitoring devices and hospital automation software sold worldwide. Its clinical product set includes advanced pulse oximetry that addresses motion and low-perfusion limits of conventional oximeters, a multi-parameter platform for hemoglobin species and oxygen-related metrics, EEG-based brain function monitoring, capnography and gas analyzers, regional oximetry and hemodynamic tools, as well as connectivity and hospital surveillance solutions. The company sells through direct sales, distributors and OEM partners to hospitals, emergency and home care providers, long-term care facilities, physician offices, veterinarians and consumers; it was founded in 1989 and is headquartered in Irvine, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 19 | Feb 26 | MASI | Masimo Corporation | Definitive $180 cash takeover by Danaher announced 2026-02-17 created a large premium and sharp momentum; stock trades below the deal price with near-term catalysts (2/26 earnings call, evolving shareholder litigation) driving an attractive event-arbitrage spread over the next few days. | Closed | -0.1% |
| Nov 17 | Nov 24 | MASI | Masimo Corporation | Q3 2025 earnings beat with strong margin expansion, increased free cash flow, positive patent infringement ruling, extended FDA clearances, and constructive technical trends near moving averages underpin Masimo as a near-term growth opportunity. | Closed | -1.0% |